top of page
Colorful Disks

Luciferase Reporter Cell Lines for Monitoring
TF Binding and Activation

Gene function analysis, target discovery and validation, assay development, and compound screening often need cell-based assays.  Stable cell lines that are engineered to express a gene of interest via transgene integrations into the host genome provide an efficient approach to conduct such analysis. 

At Signosis, we help researchers save time and labor in generating and validating stable cell lines so scientists can spend more effort on solving the big questions.  We offer a wide selection of validated Firefly luciferase reporter cell lines that measure transcription factor activity as a read-out for various signaling pathways.

We also offer Gaussia luciferase reporter cell lines, a special type of luciferase that is naturally secreted from cells, which allows for the measurement of reporter activity in the media without harming the cells. 

 

Principle

TF luciferase reporter stable cell line utilizes artificial promoter constructs to drive luciferase expression.  The promoter region can consists of multiple repeats of a cis-element TF binding site, a DNA fragment from the promoter region of a known TF downstream gene, or a DNA fragment containing putative/known TF binding sites.  There are several ways that a TF can be activated, such as through extracellular stimuli or through intracellular signaling pathways.  Once activated, the TF translocates to the nucleus and often interacts with relevant co-factors to drive gene expression.  Once luciferase is expressed, it can generate light in an enzymatic assay and the amount of light measured is positively correlated with the level of TF activation

Benefits

High Sensitivity & Responsiveness

Each cell line is validated to induce a strong reporter signal in response to stimuli, and is highly responsive to our Firefly Luciferase Substrate.

​​

Routine Mycoplasma Testing

All cell lines tested negative for mycoplasma.

Consistent

​

TF reporter construct is stably integrated into the genome to avoid experimental/cell-to-cell variations.

We also offer our own Firefly Luciferase Substrate which can generate a strong light signal that is comparable to our competitor's, but at a more cost-effective price.

Time-Saving

 

Cell line can be used for experiments right away to study different signaling pathways.

Signaling Pathways

Cell Lines

Androgen Receptor

AR

Targeted therapies for prostate cancer and other androgen-related diseases.

Calcium/
Calcineurin

NFAT

Treatments for Alzheimer's, Parkinson's, and heart disease.​

ER Stress
 

ATF4

ATF6

CHOP

​ER Stress

IRF

Development of treatments for type 2 diabetes and neurodegenerative disorders.

Glucocorticoid
Receptor

GR

Development of treatments for autoimmune and inflammatory diseases.

Hypoxia/
HIF

HIF

Development of treatments for cancer and ischemic diseases.

Inflammation/NFkB

NFkB

Development of treatments for cancer, diabetes, and inflammation.

JAK/STAT1/2
IFNalpha

IFN-α/ISRE

Development of treatments for cancer and autoimmune disorders.

MAPK/ERK/
ELK

ELK

Development of treatments for cancer and autoimmune disorders.

Metabolic Stress/AARE

Metabolic Stress

​

Development of treatments for metabolic diseases, including diabetes and obesity.

p53/
DNA Damage

p53

Development of treatments for cancer and genetic disorders.

SMAD 1/5/8
BMP

SMAD/BMP

Development of treatments for bone and cartilage disorders.

Xenobiotic Stress/Toxicity

XRE/AHR

Development of treatments for xenobiotic toxicity and related diseases.

Antioxidant Pathway

NRF2

​

Development of treatments for Alzheimer's, Parkinson's, and cancer.

cAMP/PKA/
CREB

CREB

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

Estrogen
Receptor

Estrogen Receptor

Targeted therapies for breast cancer and other estrogen-related diseases.

Heavy Metal Stress

MRF

Development of treatments for heavy metal toxicity.

Immune Response

IRF

Development of treatments for autoimmune and inflammatory diseases.

JAK/STAT1
IFNgamma

STAT1

Development of drugs for treating various diseases, including cancer and autoimmune disorders.

JAK/STAT3
 

STAT3

Development of drugs for treating various diseases, including cancer and inflammation.

MAPK/JNK/
AP-1

AP1

Development of drugs for treating various diseases, including cancer, diabetes, and inflammation.

Metabolism/
FXR

FXR

Development of drugs for treating various metabolic diseases, including liver disease and diabetes.

SMAD 2/3/4
TGF-Beta

SMAD/TGF-Beta

Development of treatments for cancer and fibrosis.

Wnt/β-Catenin
TCF/LEF

TCF/LEF

Development of treatments for cancer and bone disorders.

Products

bottom of page